all report title image
  • Published On : Sep 2022
  • Code : CMI5249
  • Industry : Pharmaceutical
  • Pages : 245
  • Formats :
Ingographics Image

Fabry disease is an inherited disorder which is caused by accumulation for globotriaosylceramide, a type of fat, in the body’s cells. Fabry disease symptoms affect body parts which include a decreased ability to sweat, events of pain in hands and feet, difficulties with the gastrointestinal system, etc. Diagnosis for fabry disease includes test such as Deoxyribonucleic acid sequence analysis, enzyme assay analysis, etc.

Treatment for fabry disease includes intravenously administered enzyme replacement therapy or oral chaperone therapy, along with this it may also need lifestyle modifications and prophylactic medications. Sometimes doctors also refer drugs to relieve pain, medicine for stomach problems, blood thinners or other drugs for an irregular heartbeat or other heart problems, blood pressure medicine, which also helps to protect kidneys. If fabry disease has caused serious kidney damage, dialysis or a kidney transplant is needed for treatment.

Market Dynamics

Survey regarding achievements or learning about fabry disease, is expected to drive growth of the LATAM fabry disease market. For instance, according to data published on June 20, 2022, by Orphanet Journal of Rare Diseases, a team of researchers had done 20 years of Fabry Outcome Survey that focused to broaden the understanding of fabry disease such as to know about the insights, achievements, and learning more about the development of fabry disease, effects of treatment, etc. according to same Route of Administration population suffering from fabry disease has reported cardiovascular problem and it was more common type of problem reported in male and female in with fabry disease in Latin America.

Updated guidelines by regulatory bodies for the development of drugs used in the treatment of fabry disease is expected to drive the LATAM fabry disease market growth. For instance, in August, 2019, the U.S. Food and Drug Administration announced the availability the draft guidance for the industries, to develop drugs for the treatment of fabry disease. This draft guidance describes the FDA’s current recommendations regarding eligibility criteria, trial design considerations, and efficacy endpoints to be used in clinical development programs of investigational drugs to treat fabry disease.

Key features of the study:

  • This report provides in-depth analysis of the LATAM fabry disease market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the LATAM fabry disease market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amicus Therapeutics, Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Mendelics, Takeda Pharmaceuticals U.S.A., Inc, Teva pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, Moderna Therapeutics Inc, and Resverlogix.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The LATAM fabry disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the LATAM fabry disease market

Detailed Segmentation:

  • LATAM Fabry Disease Market, By Therapy Type:
    • Enzyme Replacement Therapy
      • Agalsidase Beta (Fabrazyme)
      • Agalsidase Alfa (Replagal)
      • Pegunigalsidase Alfa (PRX-102, Phase III)
    • Chaperon Therapy
      • Migalastat (Galafold Phase III)
    • Substrate Reduction Therapy
      • Lucerastat (Phase III)
      • Venglustat (Phase III)
  • LATAM Fabry Disease Market, By Route of Administration:
    • Oral
    • Parental
  • LATAM fabry disease market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online pharmacies
  • LATAM Fabry Disease Market, By Country:
    • Brazil
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Mexico
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Argentina
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Rest of Latin America
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
  • Company Profiles
    • Amicus Therapeutics, Inc. *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Sanofi-Aventis U.S. LLC
    • GlaxoSmithKline plc
    • Mendelics
    • Takeda Pharmaceuticals U.S.A., Inc.
    • Teva pharmaceutical Industries Ltd
    • Pfizer Inc.,
    • Novartis AG
    • Moderna Therapeutics Inc
    • Resverlogix

 “*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • LATAM Fabry Disease Market, By Therapy Type:
    • Enzyme Replacement Therapy
      • Agalsidase Beta (Fabrazyme)
      • Agalsidase Alfa (Replagal)
      • Pegunigalsidase Alfa (PRX-102, Phase III)
    • Chaperon Therapy
      • Migalastat (Galafold Phase III)
    • Substrate Reduction Therapy
      • Lucerastat (Phase III)
      • Venglustat (Phase III)
  • LATAM Fabry Disease Market, By Route of Administration:
    • Oral
    • Parental
  • LATAM fabry disease market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online pharmacies
  • LATAM Fabry Disease Market, By Country:
    • Brazil
      • By Therapy Type
        • Enzyme Replacement Therapy
          • Agalsidase Beta (Fabrazyme)
          • Agalsidase Alfa (Replagal)
          • Pegunigalsidase Alfa (PRX-102, Phase III)
        • Chaperon Therapy
          • Migalastat (Galafold Phase III)
        • Substrate Reduction Therapy
          • Lucerastat (Phase III)
          • Venglustat (Phase III)
      • By Route of Administration
        • Oral
        • Parental
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Mexico
      • By Therapy Type
        • Enzyme Replacement Therapy
          • Agalsidase Beta (Fabrazyme)
          • Agalsidase Alfa (Replagal)
          • Pegunigalsidase Alfa (PRX-102, Phase III)
        • Chaperon Therapy
          • Migalastat (Galafold Phase III)
        • Substrate Reduction Therapy
          • Lucerastat (Phase III)
          • Venglustat (Phase III)
      • By Route of Administration
        • Oral
        • Parental
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Argentina
      • By Therapy Type
        • Enzyme Replacement Therapy
          • Agalsidase Beta (Fabrazyme)
          • Agalsidase Alfa (Replagal)
          • Pegunigalsidase Alfa (PRX-102, Phase III)
        • Chaperon Therapy
          • Migalastat (Galafold Phase III)
        • Substrate Reduction Therapy
          • Lucerastat (Phase III)
          • Venglustat (Phase III)
      • By Route of Administration
        • Oral
        • Parental
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies
    • Rest of Latin America
      • By Therapy Type
        • Enzyme Replacement Therapy
          • Agalsidase Beta (Fabrazyme)
          • Agalsidase Alfa (Replagal)
          • Pegunigalsidase Alfa (PRX-102, Phase III)
        • Chaperon Therapy
          • Migalastat (Galafold Phase III)
        • Substrate Reduction Therapy
          • Lucerastat (Phase III)
          • Venglustat (Phase III)
      • By Route of Administration
        • Oral
        • Parental
      • By Distribution Channel
        • Hospitals Pharmacies
        • Retail Pharmacies
        • Online pharmacies

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo